{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T15:58:38Z","timestamp":1771775918884,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,22]]},"DOI":"10.7759\/cureus.104062","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T15:01:37Z","timestamp":1771772497000},"source":"Crossref","is-referenced-by-count":0,"title":["Paraneoplastic Neuromyelitis Optica Spectrum Disorder Associated With Ascending Colon Cancer Expressing Aquaporin-4 and Glucose-Regulated Protein 78"],"prefix":"10.7759","author":[{"given":"Ryo","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk DM","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al.. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015, 85:177-89. 10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12288-2","article-title":"Correction to: update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel T","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O, et al.. Correction to: update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management. J Neurol. 2024, 271:3702-7. 10.1007\/s00415-024-12288-2","journal-title":"J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai9111","article-title":"Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica","volume":"9","author":"Shimizu F","year":"2017","unstructured":"Shimizu F, Schaller KL, Owens GP, et al.. Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Sci Transl Med. 2017, 9:eaai9111. 10.1126\/scitranslmed.aai9111","journal-title":"Sci Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz168","article-title":"GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome","volume":"142","author":"Shimizu F","year":"2019","unstructured":"Shimizu F, Takeshita Y, Sano Y, et al.. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome. Brain. 2019, 142:2253-64. 10.1093\/brain\/awz168","journal-title":"Brain"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4686","article-title":"Phage display derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78","volume":"67","author":"Jakobsen CG","year":"2007","unstructured":"Jakobsen CG, Rasmussen N, Laenkholm AV, Ditzel HJ. Phage display derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78. Cancer Res. 2007, 67:9507-17. 10.1158\/0008-5472.CAN-06-4686","journal-title":"Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.10.055","article-title":"Cell surface GRP78: an emerging imaging marker and therapeutic target for cancer","volume":"328","author":"Farshbaf M","year":"2020","unstructured":"Farshbaf M, Khosroushahi AY, Mojarad-Jabali S, Zarebkohan A, Valizadeh H, Walker PR. Cell surface GRP78: an emerging imaging marker and therapeutic target for cancer. J Control Release. 2020, 328:932-41. 10.1016\/j.jconrel.2020.10.055","journal-title":"J Control Release"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.30030","article-title":"Cell surface GRP78 signaling: an emerging role as a transcriptional modulator in cancer","volume":"236","author":"Gopal U","year":"2021","unstructured":"Gopal U, Pizzo SV. Cell surface GRP78 signaling: an emerging role as a transcriptional modulator in cancer. J Cell Physiol. 2021, 236:2352-63. 10.1002\/jcp.30030","journal-title":"J Cell Physiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50905","article-title":"GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica","volume":"6","author":"Shimizu F","year":"2019","unstructured":"Shimizu F, Takeshita Y, Hamamoto Y, et al.. GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica. Ann Clin Transl Neurol. 2019, 6:2079-87. 10.1002\/acn3.50905","journal-title":"Ann Clin Transl Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15479","article-title":"Investigating paraneoplastic aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder through a data-driven approach","volume":"29","author":"Dinoto A","year":"2022","unstructured":"Dinoto A, Borin GU, Campana G, Carta S, Ferrari S, Mariotto S. Investigating paraneoplastic aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder through a data-driven approach. Eur J Neurol. 2022, 29:3466-72. 10.1111\/ene.15479","journal-title":"Eur J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1071519","article-title":"Neuromyelitis optica spectrum disorders associated with AQP4-positive-cancer-a case series","volume":"13","author":"Duan Y","year":"2022","unstructured":"Duan Y, Wang X, Duan X, et al.. Neuromyelitis optica spectrum disorders associated with AQP4-positive-cancer-a case series. Front Neurol. 2022, 13:1071519. 10.3389\/fneur.2022.1071519","journal-title":"Front Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9783-22","article-title":"Paraneoplastic neuromyelitis optica spectrum disorder related to glucose-regulated protein 78 (GRP78) autoantibodies in a patient with Lynch syndrome-associated colorectal cancer","volume":"62","author":"Minomo S","year":"2023","unstructured":"Minomo S, Ichijo M, Shimizu F, et al.. Paraneoplastic neuromyelitis optica spectrum disorder related to glucose-regulated protein 78 (GRP78) autoantibodies in a patient with Lynch syndrome-associated colorectal cancer. Intern Med. 2023, 62:1653-7. 10.2169\/internalmedicine.9783-22","journal-title":"Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius S","year":"2008","unstructured":"Jarius S, Aboul-Enein F, Waters P, et al.. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008, 131:3072-80. 10.1093\/brain\/awn240","journal-title":"Brain"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim SH","year":"2013","unstructured":"Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013, 70:1110-7. 10.1001\/jamaneurol.2013.3071","journal-title":"JAMA Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2018.1531190","article-title":"Blood-brain barrier dysfunction in immuno-mediated neurological diseases","volume":"41","author":"Shimizu F","year":"2018","unstructured":"Shimizu F, Nishihara H, Kanda T. Blood-brain barrier dysfunction in immuno-mediated neurological diseases. Immunol Med. 2018, 41:120-8. 10.1080\/25785826.2018.1531190","journal-title":"Immunol Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3892\/or_00000719","article-title":"Proteomics-based identification of a tumor-associated antigen and its corresponding autoantibody in gastric cancer","volume":"23","author":"Tsunemi S","year":"2010","unstructured":"Tsunemi S, Nakanishi T, Fujita Y, et al.. Proteomics-based identification of a tumor-associated antigen and its corresponding autoantibody in gastric cancer. Oncol Rep. 2010, 23:949-56. 10.3892\/or_00000719","journal-title":"Oncol Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001038","article-title":"GRP78 antibodies are associated with blood-brain barrier breakdown in anti-myelin oligodendrocyte glycoprotein antibody-associated disorder","volume":"9","author":"Shimizu F","year":"2022","unstructured":"Shimizu F, Ogawa R, Mizukami Y, et al.. GRP78 antibodies are associated with blood-brain barrier breakdown in anti-myelin oligodendrocyte glycoprotein antibody-associated disorder. Neurol Neuroimmunol Neuroinflamm. 2022, 9:e1038. 10.1212\/NXI.0000000000001038","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2005.07.016","article-title":"Overexpression of glucose-regulated protein 78 in colon cancer","volume":"364","author":"Xing X","year":"2006","unstructured":"Xing X, Lai M, Wang Y, Xu E, Huang Q. Overexpression of glucose-regulated protein 78 in colon cancer. Clin Chim Acta. 2006, 364:308-15. 10.1016\/j.cca.2005.07.016","journal-title":"Clin Chim Acta"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910625","article-title":"Blood-brain barrier disruption in neuroimmunological disease","volume":"25","author":"Shimizu F","year":"2024","unstructured":"Shimizu F, Nakamori M. Blood-brain barrier disruption in neuroimmunological disease. Int J Mol Sci. 2024, 25:10625. 10.3390\/ijms251910625","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/360401-paraneoplastic-neuromyelitis-optica-spectrum-disorder-associated-with-ascending-colon-cancer-expressing-aquaporin-4-and-glucose-regulated-protein-78","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T15:01:38Z","timestamp":1771772498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/360401-paraneoplastic-neuromyelitis-optica-spectrum-disorder-associated-with-ascending-colon-cancer-expressing-aquaporin-4-and-glucose-regulated-protein-78"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.104062","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,22]]}}}